clinical studies on SENOLYSE – so far these have not taken place

Senolysis is a promising therapeutic concept for many chronic degenerative disorders and diseases, even all age-related decline.

So exciting is zombicell senolysis that clinical trials are now being conducted worldwide (I thought) – most of them so new that we don’t have results yet. 

However, while researching this article, it has become clearer and clearer to me that since about 2019 everything has ground to a halt and we hardly get any more clinical research (using human patients) on the topic.

NB: here I found a nice article about SENESCENCE and SENOLYSIS in the spectrum of science that is not hidden behind a paywall (sorry, german edition)

 

STUDIES

mouse studies have come together relatively quickly. Only when these show promise and there are no serious concerns about side effects etc. can clinical trials in humans be attempted. Due to a variety of administrative hurdles, this is not so easy and strictly regulated.

 

Tony Robbins Life Force

the book by Tony Robbins and Prof. David Sinclair has really brought ANTI-AGING and new treatment concepts such as senolysis into the focus of public attention.

See Tony Robbins’ interview about his own stem cell therapy in Panama and his new book LIFE-FORCE which was published 4 months ago

I’ve worked through the first 14 of 24 chapters of Life Force so far, I have to keep doing research and I’ve benefited endlessly from it

 

 

In this context, another titan of REGENERATIVE research and anti-aging medicine should be pointed out:

David Sinclair’s “The End of Aging”

Here is my detailed article about David Sinclair and below the exciting book that came out 1 year ago

 

You can read and see a lot about senolysis – ultimately in the last few years they announced many clinical studies

 

Well, where are the studies now?

finally it hit me: Lockdown of C**na-Vyrus stopped the studies and postponed them

 

current review in the LANCET on senolysis

A review from 2022 in the Lancet Longevity summarizes the current clinical studies and it was only when I was writing this article that I noticed that no new clinical study on dasatinib has come out since 2019 !

 

Studies have already been successfully carried out in the mouse model

there are very diverse studies up to 2019 – quoted here from the review

• Kidney : function, regeneration of tubules, reduced scarring
• Metabolism : insulin, lipid-StW, inflammation, fatty liver decreased (one study: slightly increased fatty liver)
• Heart : improved function, less inflammation, inhibited atherosclerosis, reduced scarring and hypertrophy
• Muscle : endurance, improved recovery
• Bone marrow and bone: rejuvenation of blood formation, decrease in osteoporosis – Aggravations: induction of thrombocytopenia, decreased bone trabeculae
• Lungs : improvement in pulmonary blood flow, better lung function, reduced scarring
• Brain : less deposits (Alzheimer’s), less inflammation, less degradation of the retina
• Skin : fewer moles and growths, increase in hair follicles

the corresponding studies can be easily viewed via the LANCET-Review, the study is linked in the graphic above.

 

 

but what about the human clinical trials?

Are there any side effects of senolysis?

so far I can’t remember any official pharmacological therapy with so few side effect studies! 

The existing side effects are certainly due to the leukemia drug dasatinib , which therefore mainly affects the bone marrow and platelets.

 

dr James Kirkland, Mayo Clinic

1 year ago here an interview with the main researcher Dr. James Kirkland, Mayo Clinic , currently conducting 4 patient clinical studies and co-authoring 186 articles .

 

as well as here a presentation as part of a reverse aging congress

 

There hasn’t been anything new from Kirkland on Youtube for 8 months ! Even the studies he started 4 years ago aren’t going any further!

 

 

clinical studies with humans are somehow missing

the switch from the research laboratory from mice to humans is being carried out quickly in countries such as Mexico, Costa Rica, Panama, Cuba, etc., because of course there is a great need in the rich countries – especially the USA.

I have written and referenced it several times elsewhere (“ Article with TAG Senolyse ”).

In fact, I thought the “hype” was producing a lot of studies, but actually I only found 14 clinical studies currently listed in the NIH database: 14 clinical studies on senolysis and they all look pretty inactive.

There is actually a total dead end for this hot topic with such fascinating implications.

I wrote to the author of the Alzheimer’s study weeks ago and didn’t get an answer!

 

only a small study in 2019 with 7 participants

Diabetic nephropathy (kidney damage from diabetes) : 7 patients underwent senolysis. The systemic effectiveness of senolysis was proven by conducting fat tissue biopsies and examining the content of zombi cells and finding a significant reduction.

 

there was a reduction in the number of SENSCENT CELLS in the FAT TISSUE from about 80% to 30% after 2 weeks, measured by the number of ß-galactosidase-expressing cells

 

at the same time to a REGENERATION of the adipose tissue by increasing the “newly formed regeneration cells” from 47 to 53%

Below then the reduction in inflammation in the adipose tissue visible through the number of inflammatory cells, macrophages and the massive disappearance of DEAD Adipocytes in the adipose tissue ( Crown Like Structures )

 

the same result could be seen in the skin biopsies of the patients.

Unfortunately, the study does not provide any information on kidney function and its changes, but a warning: so far (2019) only 150 people have been treated in this way, so you should be aware that this is a potentially dangerous therapy. 

Nothing since then? There are only 14 studies active and they seem to have been “recruiting” for many years?

 

Is this because of the danger of the therapy?

About the half-life of the drugs used

80% of the drugs are out of the body within 24 hours , which is why a “hit and run” strategy is often used: intermittent doses of the drugs every few weeks or months.

The currently most famous researcher Dr. Mayo Clinic’s Kirkland says that you don’t have to repeat this strategy often because the affected zombi cells die off with therapy, permanently reducing their harmful impact.

These senescent zombie cells are naturally reproduced “through the aging” of the normal, active cells, but this takes some time.

 

Dasatinib as a drug

this senolytic drug has been used in leukemia therapy for years. You can probably read a little about the danger of this drug from the package insert:

Application also permitted in small children (10-20 kg body weight), up to 2 years duration with daily administration, also an application in addition to another chemotherapy, longer-term use – longer than 2 years – must be assessed by the specialist.

No dose adjustment is necessary in elderly patients or in patients with liver damage ,

since it does not go through the kidneys, a weakness in kidney function is not a reason for exclusion.

In oncology, for safety and to control side effects, the following is recommended:

in adult patients and children and adolescents, a complete blood count should be performed every 2 weeks for the first 12 weeks , then every 3 months or as clinically indicated.

somehow doesn’t sound as if this drug is extremely dangerous and that clinical studies could not be carried out under any circumstances?

In my practice I have leukemia patients who have been using this drug daily for 4 years or more. 

 

personal comment on the lack of clinical studies

we will certainly need a few more years until this therapy concept is fully developed. Until then you can get it in Costa Rica, Mexico or Panama and from there the information will slowly become public.

In any case, research on mice is active, in humans it doesn’t seem to be getting off the ground and has been standing still for some time, I only noticed that when I was writing this article!!

I actually thought I could present a collection of the successful senolysis studies here: yes, but only in the mouse!

 

was to be expected…

Anyone who has been following the mechanisms of my industry for a long time knows that one of the most successful sectors of the economy ( approx. 10% GDP ) cannot simply be stripped of its economic basis through rejuvenation and recovery.

That’s why Osman Kibar’s incredible discovery on cancer therapy – presented in the Vatican in 2018 – will certainly not be put into practice in my lifetime:

 

invisible glass ceiling that makes you hit your head

This glass ceiling is quoted from Nick Gonzales at a seminar I attended with him:

when he treated 20 healed pancreatic carcinoma patients who were referred to him by the NIH as part of a joint study and who, according to his statement, were quite badly with each other and unexpectedly got well with his therapy,

when he wanted to publish this he did not and did not succeed, although his investigation was even suggested and commissioned by the NIH.

dr Gonzales finally documented his experiences in a book “One Man Allone“

 

more about Dr. Gonzalez therapy

 

Oh yes, Dr. Gonzalez, like his practice colleague shortly thereafter, was left early as part of the Obama purge of holistic physicians, I wrote an article about it:  “Holistic Physician Deaths in the USA “